Immunotherapy drug tested against rare adrenal cancer
NCT ID NCT02673333
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests the immunotherapy drug pembrolizumab in 39 people with advanced adrenocortical carcinoma that cannot be removed by surgery. The study aims to see if the drug can shrink or control the cancer. Participants receive pembrolizumab and are monitored for tumor response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (immunotherapy drug)
What this could lead to
If successful, this could offer a new treatment option for advanced adrenocortical carcinoma, a rare and aggressive cancer with limited therapies.
What could go wrong
This is a small, early-phase trial (39 people) with no control group. The drug may not shrink tumors in enough patients to be considered promising, and immunotherapy can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
University of Michigan (Data or Specimen Analysis Only)
Ann Arbor, Michigan, 48109, United States